Publications by authors named "J W Copland"
BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression.
Front Endocrinol (Lausanne)
December 2024
Introduction: BRAFV600E mutation (BRAF) is common in papillary thyroid cancer (PTC), and most patients have an excellent outcome. However, a TERT-promoter mutation (pTERT) in the presence of BRAF (BRAFpTERT) has been demonstrated to confer a more aggressive behavior to PTC. Lymphocytic infiltration is often present in PTC.
View Article and Find Full Text PDFArticle Synopsis
- MSC therapy shows promise for treating neurological diseases by repairing organ damage through specific cell differentiation and paracrine mechanisms.
- * iPSC-derived MSCs (iMSCs) can produce neurotrophic factors that enhance neuronal survival, growth, and metabolic activity, making them a valuable resource for regenerative medicine.
- * Research indicates that iMSC therapy can improve brain function after injury, as shown by increased glucose uptake in brain imaging and restored synaptic activity in mouse models.
Article Synopsis
- Matrix metalloproteinases (MMPs) are key players in various diseases, especially cancer, making tissue inhibitors of metalloproteinases (TIMPs) important for drug development as they effectively inhibit MMPs.
- A major issue with TIMPs, however, is their quick clearance from the bloodstream because of their small size.
- This study presents a solution by extending the half-life of TIMP2's N-terminal domain (N-TIMP2) through a process called PATylation, resulting in variants that show increased plasma half-life and maintained inhibitory potency against MMP-9, paving the way for better MMP-targeted therapies.
Purpose: Thyroid-stimulating hormone receptor (TSHR) is a G-protein coupled receptor that is highly expressed on benign and malignant thyroid tissues. TSHR binding and activation has long been a component of thyroid cancer molecular imaging and radiotherapy, by promoting expression of the sodium-iodide symporter (NIS) and incorporation of I-131 into thyroid hormones. Here, we report the radiosynthesis and preclinical evaluation of a Zirconium-89 (Zr) labeled TSHR antibody to serve as a positron emission tomography (PET) diagnostic correlate for therapeutic agents targeting TSHR without reliance on NIS.
View Article and Find Full Text PDFMatrix Metalloproteinases (MMPs) are drivers of many diseases including cancer and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are human proteins that inhibit MMPs and are being pursued for the development of anti-MMP therapeutics. TIMPs possess many attractive properties of a drug candidate, such as complete MMP inhibition, low toxicity and immunogenicity, high tissue permeability and others.
View Article and Find Full Text PDF